Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $41.52
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Aug 18, 26 | Mizuho | maintain | Outperform | Outperform |
| Aug 6, 26 | Goldman Sachs | maintain | Buy | Buy |
| Aug 6, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 6, 26 | Stifel | maintain | Buy | Buy |
| Jul 21, 26 | Goldman Sachs | maintain | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 1, 26 | Stifel | maintain | Buy | Buy |
| Jun 29, 26 | Jones Trading | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.94 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 49.64 | Oscillator | Neutral |
| Williams %R (14) | -47.28 | Oscillator | Neutral |
| MACD (12, 26, 9) | -2.55 (Hist 0.58) | Oscillator | Buy |
| Average Directional Index (14) | 45.12 (+DI 19.1 / -DI 30.6) | Trend | Strong Sell |
| EMA 20 | 42.68 | MA | Sell |
| SMA 20 | 42.19 | MA | Sell |
| EMA 50 | 46.89 | MA | Strong Sell |
| SMA 50 | 50.25 | MA | Strong Sell |
| SMA 200 | 42.27 | MA | Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 19, 26 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | M-Exempt | 6,018 @ $14.85 | $89.37K |
| Oct 19, 26 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | M-Exempt | 6,018 @ $14.85 | $89.37K |
| Oct 19, 26 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | S-Sale | 6,018 @ $38.48 | $231.5K |
| Oct 19, 26 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 @ $2.48 | $12.40K |
| Oct 19, 26 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 @ $2.48 | $12.40K |
| Oct 19, 26 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | S-Sale | 5,000 @ $38.47 | $192.3K |
| Oct 14, 26 | Ball Kristine M | director | A-Award | 23,394 @ $39.28 | $918.9K |
| Oct 14, 26 | Ball Kristine M | 0 | — |
Stock news · updated daily
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to initiate the pivotal Phase 3 trial of relcobatinib before year-end BURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Kristine Ball to its Board of Directors, effective immediately.
Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.39 | -0.49 | Miss -26.6% | — |
| May 7, 2026 | -0.44 | -0.38 | Beat 13.6% | — |
| Mar 3, 2026 | -0.42 | -0.48 | Miss -14.3% | — |
| Nov 12, 2025 | -0.43 | -0.32 | Beat 25.6% | — |
| Aug 13, 2025 | -0.53 | -0.49 | Beat 7.5% | — |
| May 14, 2025 | -0.51 | -0.57 | Miss -11.8% | — |
| 8-K | Oct 14, 2026 | 2026-10-14 16:39:15 | View |
| 4 | Oct 5, 2026 | 2026-10-05 16:57:04 | View |
| 4 | Sep 21, 2026 | 2026-09-21 17:23:41 | View |
| 4 | Sep 21, 2026 | 2026-09-21 17:22:07 | View |
| 4 | Aug 19, 2026 | 2026-08-19 16:17:49 | View |
| 4 | Aug 19, 2026 | 2026-08-19 16:16:13 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ELVN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -25.3x | -6.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -22.4x | EPS est. -1.86 | In line |
| Price / Book | 3.1x | 1.3x | Elevated |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -27.5x | -4.5x | Elevated |
| Return on equity | -18.5% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | -0.00 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 122.46 | Safe zone |
Discounted cash flow model